Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.78
VRTX's Cash to Debt is ranked higher than
60% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. VRTX: 1.78 )
VRTX' s 10-Year Cash to Debt Range
Min: 0.92   Max: 26.61
Current: 1.78

0.92
26.61
Equity to Asset 0.48
VRTX's Equity to Asset is ranked higher than
62% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VRTX: 0.48 )
VRTX' s 10-Year Equity to Asset Range
Min: -0.02   Max: 0.95
Current: 0.48

-0.02
0.95
F-Score: 4
Z-Score: 9.77
M-Score: -3.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -119.41
VRTX's Operating margin (%) is ranked higher than
70% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. VRTX: -119.41 )
VRTX' s 10-Year Operating margin (%) Range
Min: -602.63   Max: 8.07
Current: -119.41

-602.63
8.07
Net-margin (%) -127.25
VRTX's Net-margin (%) is ranked higher than
69% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. VRTX: -127.25 )
VRTX' s 10-Year Net-margin (%) Range
Min: -630.27   Max: 2.1
Current: -127.25

-630.27
2.1
ROE (%) -61.43
VRTX's ROE (%) is ranked higher than
65% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. VRTX: -61.43 )
VRTX' s 10-Year ROE (%) Range
Min: -180.27   Max: 4.58
Current: -61.43

-180.27
4.58
ROA (%) -32.46
VRTX's ROA (%) is ranked higher than
72% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. VRTX: -32.46 )
VRTX' s 10-Year ROA (%) Range
Min: -58.14   Max: 1.51
Current: -32.46

-58.14
1.51
ROC (Joel Greenblatt) (%) -96.53
VRTX's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. VRTX: -96.53 )
VRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1034.2   Max: 110.77
Current: -96.53

-1034.2
110.77
Revenue Growth (3Y)(%) 95.60
VRTX's Revenue Growth (3Y)(%) is ranked higher than
65% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. VRTX: 95.60 )
VRTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -32.4   Max: 130.2
Current: 95.6

-32.4
130.2
EBITDA Growth (3Y)(%) 2.60
VRTX's EBITDA Growth (3Y)(%) is ranked lower than
115% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. VRTX: 2.60 )
VRTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17   Max: 105.6
Current: 2.6

-17
105.6
EPS Growth (3Y)(%) -19.30
VRTX's EPS Growth (3Y)(%) is ranked lower than
115% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. VRTX: -19.30 )
VRTX' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.7   Max: 94.5
Current: -19.3

-48.7
94.5
» VRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

VRTX Guru Trades in Q1 2014

Jim Simons 312,164 sh (New)
George Soros 10,000 sh (New)
John Burbank 2,872 sh (New)
Steven Cohen 114,954 sh (New)
Vanguard Health Care Fund 11,628,500 sh (+5.89%)
Pioneer Investments 1,195,955 sh (-1.7%)
» More
Q2 2014

VRTX Guru Trades in Q2 2014

Ken Fisher 6,753 sh (New)
Paul Tudor Jones 2,178 sh (New)
Vanguard Health Care Fund 11,807,500 sh (+1.54%)
Steven Cohen 934,700 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
John Burbank Sold Out
Pioneer Investments 850,152 sh (-28.91%)
» More
Q3 2014

VRTX Guru Trades in Q3 2014

Stanley Druckenmiller 146,600 sh (New)
Paul Tudor Jones 7,726 sh (+254.73%)
Vanguard Health Care Fund 11,807,500 sh (unchged)
Pioneer Investments 661,813 sh (unchged)
Ken Fisher 4,593 sh (-31.99%)
Steven Cohen 443,300 sh (-52.57%)
» More
Q4 2014

VRTX Guru Trades in Q4 2014

Andreas Halvorsen 764,200 sh (New)
Stanley Druckenmiller Sold Out
Pioneer Investments 647,257 sh (-2.2%)
Ken Fisher 4,378 sh (-4.68%)
Paul Tudor Jones 6,589 sh (-14.72%)
Vanguard Health Care Fund 9,808,860 sh (-16.93%)
Steven Cohen 16,500 sh (-96.28%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-12-31 Reduce -16.93%0.58%$101.1 - $120.78 $ 120.177%9808860
Andreas Halvorsen 2014-12-31 New Buy0.42%$101.1 - $120.78 $ 120.177%764200
Ken Fisher 2014-09-30 Reduce -31.99%$84.74 - $113.9 $ 120.1726%4593
John Burbank 2014-06-30 Sold Out 0.01%$62.44 - $93.77 $ 120.1772%0
George Soros 2014-06-30 Sold Out 0.01%$62.44 - $93.77 $ 120.1772%0
Ken Fisher 2014-06-30 New Buy$62.44 - $93.77 $ 120.1772%6753
Vanguard Health Care Fund 2014-03-31 Add 5.89%0.13%$67.8 - $85.48 $ 120.1752%11628500
George Soros 2014-03-31 New Buy0.01%$67.8 - $85.48 $ 120.1752%10000
John Burbank 2014-03-31 New Buy0.01%$67.8 - $85.48 $ 120.1752%2872
Vanguard Health Care Fund 2013-12-31 Add 54.06%0.88%$60.18 - $77.83 $ 120.1773%10981500
Vanguard Health Care Fund 2013-09-30 Add 19%0.29%$74.53 - $88.51 $ 120.1751%7127997
Vanguard Health Care Fund 2013-06-30 Add 140.58%1.05%$52.6 - $85.6 $ 120.1763%5990000
Andreas Halvorsen 2013-06-30 Sold Out 0.26%$52.6 - $85.6 $ 120.1763%0
NWQ Managers 2013-06-30 Sold Out 0.09%$52.6 - $85.6 $ 120.1763%0
Andreas Halvorsen 2013-03-31 New Buy0.26%$41.9 - $54.97 $ 120.17151%780500
NWQ Managers 2013-03-31 Reduce -23.44%0.02%$41.9 - $54.97 $ 120.17151%191032
Daniel Loeb 2012-12-31 Sold Out 0.77%$38.88 - $59.42 $ 120.17161%0
John Burbank 2012-12-31 Sold Out 0.38%$38.88 - $59.42 $ 120.17161%0
Daniel Loeb 2012-09-30 Add 40%0.22%$48.38 - $59.07 $ 120.17125%700000
John Burbank 2012-09-30 Reduce -25%0.09%$48.38 - $59.07 $ 120.17125%150000
George Soros 2012-09-30 Sold Out 0.09%$48.38 - $59.07 $ 120.17125%0
Joel Greenblatt 2012-09-30 Sold Out 0.08%$48.38 - $59.07 $ 120.17125%0
John Hussman 2012-06-30 Sold Out 0.93%$35.75 - $65.62 $ 120.17136%0
Daniel Loeb 2012-06-30 New Buy0.85%$35.75 - $65.62 $ 120.17136%500000
John Burbank 2012-06-30 New Buy0.38%$35.75 - $65.62 $ 120.17136%200000
NWQ Managers 2012-06-30 Reduce -83.86%0.27%$35.75 - $65.62 $ 120.17136%188842
Joel Greenblatt 2012-06-30 New Buy0.08%$35.75 - $65.62 $ 120.17136%20025
George Soros 2012-06-30 Reduce -44%0.05%$35.75 - $65.62 $ 120.17136%112000
Jean-Marie Eveillard 2012-06-30 Sold Out 0.02%$35.75 - $65.62 $ 120.17136%0
John Hussman 2012-03-31 Reduce -35%0.34%$32.2 - $42.94 $ 120.17234%1170000
Ray Dalio 2012-03-31 Sold Out 0.24%$32.2 - $42.94 $ 120.17234%0
George Soros 2012-03-31 New Buy0.12%$32.2 - $42.94 $ 120.17234%200000
Jean-Marie Eveillard 2012-03-31 New Buy0.02%$32.2 - $42.94 $ 120.17234%110000
John Hussman 2011-12-31 New Buy0.96%$26.6 - $45.12 $ 120.17242%1800000
NWQ Managers 2011-12-31 New Buy0.26%$26.6 - $45.12 $ 120.17242%1223740
Ray Dalio 2011-12-31 Add 1038.59%0.22%$26.6 - $45.12 $ 120.17242%437458
Vanguard Health Care Fund 2011-12-31 Add 9.59%0.04%$26.6 - $45.12 $ 120.17242%2743700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 24.88
VRTX's Forward P/E is ranked higher than
93% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: 24.88 )
N/A
P/B 26.20
VRTX's P/B is ranked higher than
58% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. VRTX: 26.20 )
VRTX' s 10-Year P/B Range
Min: 4.13   Max: 37
Current: 26.2

4.13
37
P/S 35.40
VRTX's P/S is ranked higher than
72% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. VRTX: 35.40 )
VRTX' s 10-Year P/S Range
Min: 4.47   Max: 80.48
Current: 35.4

4.47
80.48
EV-to-EBIT -33.63
VRTX's EV-to-EBIT is ranked higher than
53% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: -33.63 )
VRTX' s 10-Year EV-to-EBIT Range
Min: -40   Max: 4164.9
Current: -33.63

-40
4164.9
Current Ratio 4.43
VRTX's Current Ratio is ranked higher than
72% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. VRTX: 4.43 )
VRTX' s 10-Year Current Ratio Range
Min: 1.73   Max: 30.95
Current: 4.43

1.73
30.95
Quick Ratio 4.39
VRTX's Quick Ratio is ranked higher than
73% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. VRTX: 4.39 )
VRTX' s 10-Year Quick Ratio Range
Min: 1.62   Max: 30.95
Current: 4.39

1.62
30.95
Days Inventory 101.73
VRTX's Days Inventory is ranked higher than
90% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: 101.73 )
VRTX' s 10-Year Days Inventory Range
Min: 62.49   Max: 254.87
Current: 101.73

62.49
254.87
Days Sales Outstanding 45.90
VRTX's Days Sales Outstanding is ranked higher than
86% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. VRTX: 45.90 )
VRTX' s 10-Year Days Sales Outstanding Range
Min: 25.75   Max: 106.15
Current: 45.9

25.75
106.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 125.71
VRTX's Price/Net Cash is ranked higher than
72% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. VRTX: 125.71 )
VRTX' s 10-Year Price/Net Cash Range
Min: 3.55   Max: 410.43
Current: 125.71

3.55
410.43
Price/Net Current Asset Value 89.12
VRTX's Price/Net Current Asset Value is ranked higher than
71% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. VRTX: 89.12 )
VRTX' s 10-Year Price/Net Current Asset Value Range
Min: 3.43   Max: 191.53
Current: 89.12

3.43
191.53
Price/Tangible Book 27.97
VRTX's Price/Tangible Book is ranked higher than
62% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. VRTX: 27.97 )
VRTX' s 10-Year Price/Tangible Book Range
Min: 2.9   Max: 75.48
Current: 27.97

2.9
75.48
Price/Median PS Value 2.11
VRTX's Price/Median PS Value is ranked higher than
72% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. VRTX: 2.11 )
VRTX' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 4.51
Current: 2.11

0.3
4.51
Earnings Yield (Greenblatt) -3.00
VRTX's Earnings Yield (Greenblatt) is ranked higher than
81% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. VRTX: -3.00 )
VRTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 5.3
Current: -3

1.4
5.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VX1.Germany, VRTX.Mexico,
Vertex Pharmaceuticals Inc was incorporated in Massachusetts in 1989. The Company is engaged in the business of discovering, developing and commercializing small molecule drugs. The Company's two products are INCIVE (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus, or HCV, infection; and KALYDEC (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis, or CF, who genetic mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. As the Company markets and sells its approved products and advances its drug candidates through clinical development toward commercialization, it continues to build and maintain its supply chain and quality assurance resources. The Company face competition based on the safety and efficacy of its products and drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record keeping, promotion, advertising, distribution and marketing of its products and drug candidates are subject to extensive regulation by United States and foreign governmental authorities.
» More Articles for VRTX

Headlines

Articles On GuruFocus.com
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
Vertex Could Climb On New Drug, VX-222 Success Apr 21 2012 


More From Other Websites
Short Sellers Come Back To Biotech Stocks Feb 26 2015
PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer Feb 25 2015
Biotech on the rise; Analyst likes Gilead Feb 23 2015
What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results Feb 23 2015
Nordstrom climbs on earnings; Noodles, Avon slump Feb 20 2015
Lysosomal Therapeutics to use $20M to develop, test Parkinson's drug Feb 20 2015
VERTEX PHARMACEUTICALS INC / MA Financials Feb 20 2015
Short Sellers Retreat From Biotech Stocks Feb 12 2015
Vertex to Present at Upcoming Investor Conferences Feb 11 2015
Vertex to Present at Upcoming Investor Conferences Feb 11 2015
Stock Market News for February 06, 2015 - Market News Feb 06 2015
[$$] Arkansas Reaches Settlement in Cystic Fibrosis Drug Suit Feb 06 2015
First Hand Account: The White House Precision Medicine Announcement Jan 31 2015
In cystic fibrosis drug launch prep, Vertex learns from Sovaldi mistakes Jan 30 2015
Obama unveils precision medicine initiative Jan 30 2015
Vertex Pharmaceuticals Slumps: VRTX Falls 5.9% in Session - Tale of the Tape Jan 30 2015
White House targets precision medicine Jan 30 2015
Baird Releases Comments After Vertex Earnings Call Jan 29 2015
Vertex head of research, Broad co-founder David Altshuler to meet with Obama Friday Jan 29 2015
Vertex Pharma Verging on Full Valuation Jan 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK